World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
124
Citations
66173
World Ranking
3191
National Ranking
1764

Richard E. Chaisson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard E. Chaisson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 500 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard E. Chaisson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard E. Chaisson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 124 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Richard E. Chaisson is affiliated with Johns Hopkins University in the United States. Their research primarily focuses on Medicine, with a particular emphasis on Infectious Diseases, Epidemiology, Surgery, Pediatrics, Perinatology and Child Health, and Public Health, Environmental and Occupational Health.

Their work covers several key topics, including:

  • Tuberculosis Research and Epidemiology
  • Pneumocystis jirovecii pneumonia detection and treatment
  • HIV/AIDS drug development and treatment
  • Infectious Diseases and Tuberculosis
  • Pneumonia and Respiratory Infections
  • Mycobacterium research and diagnosis
  • HIV/AIDS Research and Interventions

The scientist has published extensively in multiple venues. Frequent publication venues include:

  • The International Journal of Tuberculosis and Lung Disease
  • Clinical Infectious Diseases
  • IJTLD OPEN
  • The Lancet HIV
  • American Journal of Respiratory and Critical Care Medicine

Richard E. Chaisson's recent papers highlight ongoing research interests and contributions to the field. Notable publications include:

  • "Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis," 2021, New England Journal of Medicine
  • "Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis," 2023, The Lancet
  • "Clinical standards for the diagnosis, treatment and prevention of TB infection," 2022, The International Journal of Tuberculosis and Lung Disease
  • "Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial," 2020, The Lancet HIV
  • "A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB," 2021, The International Journal of Tuberculosis and Lung Disease

Frequent co-authors collaborating with Richard E. Chaisson include:

  • Susan Swindells
  • Gavin Churchyard
  • Kelly E. Dooley
  • Neil Martinson
  • Payam Nahid

Richard E. Chaisson has been recognized as a Member of the Association of American Physicians.

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy

    Diana Finzi;Monika Hermankova;Theodore Pierson;Lucy M. Carruth

  • Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

    Diana Finzi;Joel N Blankson;Janet M Siliciano;Joseph Bernard Margolick

  • American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

    Henry M Blumberg;William J Burman;Richard E Chaisson;Charles L Daley

  • Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

    Payam Nahid;Susan E. Dorman;Narges Alipanah;Pennan M. Barry

  • Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

    Mark S. Sulkowski;David L. Thomas;Richard E. Chaisson;Richard D. Moore

  • Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

    Timothy R. Sterling;M. Elsa Villarino;Andrey S. Borisov;Nong Shang

  • Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.

    Gregory M. Lucas;Richard E. Chaisson;Richard D. Moore

  • Latent Mycobacterium tuberculosis Infection

    Haileyesus Getahun;Alberto Matteelli;Richard E. Chaisson;Mario Raviglione

  • Cocaine use and HIV infection in intravenous drug users in San Francisco.

    Richard E. Chaisson;Peter Bacchetti;Dennis Osmond;Barbara Brodie

  • Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort.

    Andrew R. Moss;Peter Bacchetti;Dennis Osmond;Walter Krampf

  • Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine

    Joel E. Gallant;Richard D. Moore;Richard D. Moore;Douglas D. Richman;Douglas D. Richman;Jeanne Keruly;Jeanne Keruly

  • Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.

    Mark S. Sulkowski;David L. Thomas;David L. Thomas;Shruti H. Mehta;Richard E. Chaisson

  • Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.

    Haileyesus Getahun;Alberto Matteelli;Ibrahim Abubakar;Mohamed Abdel Aziz

  • Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.

    Peter M. Small;Gisela F. Schecter;Philip C. Goodman;Merle A. Sande

  • Natural history of HIV infection in the era of combination antiretroviral therapy.

    Richard D. Moore;Richard E. Chaisson

  • Hepatitis C and progression of HIV disease.

    Mark S. Sulkowski;Richard D. Moore;Shruti H. Mehta;Richard E. Chaisson

  • USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus

    David Lanier;Neil Schram;Ellen Cooper;Kenneth A. Freedberg

  • Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival.

    Richard E. Chaisson;Gisela F. Schecter;Charles P. Theuer;George W. Rutherford

  • Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial

    Debra Benator;Mondira Bhattacharya;Lorna Bozeman;William Burman

Frequent Co-Authors

Richard D. Moore
Richard D. Moore Johns Hopkins University
Gavin J. Churchyard
Gavin J. Churchyard Aurum Institute
William R. Bishai
William R. Bishai Johns Hopkins University
Katherine Fielding
Katherine Fielding University of London
Lawrence H. Moulton
Lawrence H. Moulton Johns Hopkins University
Jean B. Nachega
Jean B. Nachega University of Pittsburgh
Elizabeth L. Corbett
Elizabeth L. Corbett London School of Hygiene & Tropical Medicine
Gary Maartens
Gary Maartens University of Cape Town
Timothy R. Sterling
Timothy R. Sterling Vanderbilt University Medical Center
Eric L. Nuermberger
Eric L. Nuermberger Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens many doors beyond a traditional MD degree. There are several flexible online degree options that can help you launch or advance your career in healthcare. For those interested in clinical care, some students are drawn to nursing. In fact, there are nursing school without teas test requirements, allowing prospective nurses to enroll without standardized entry exams, which can streamline the application process.

If you are interested in leadership, business, or hospital management, you might explore healthcare administration degrees. These programs, often available in accelerated formats, prepare graduates for management roles in a rapidly growing industry.

Registered nurses seeking further specialization can pursue rn to fnp bridge programs, which allow RNs to earn their MSN and become Family Nurse Practitioners through efficient bridge curricula.

For those interested in preventive health or dietetics, an online nutrition degree can provide the foundation for work in wellness, sports nutrition, or public health.

Each of these online health programs offers unique pathways tailored to different interests and career goals, making healthcare education more accessible than ever.

Best Scientists Citing Richard E. Chaisson

Trending Scientists

Recently Published Articles